EuroBiotech: More Articles of Note


> Hookipa Pharma priced its IPO at $14 (€12) a share, setting it up to raise $84 million. The money will enable Hookipa to take a cytomegalovirus infection candidate through phase 2. Release 

> Affimed provided the FDA with information it hopes will lead to the lifting of the clinical hold on AFM11. The German biotech expects to receive an update from the FDA in the second quarter. Statement 

> Cassiopea posted 12-month data from a phase 2 trial of androgenic alopecia treatment Breezula. The trial met one of its two co-primary endpoints. Release 


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

> Silence Therapeutics named Giles Campion as head of R&D and chief medical officer. Campion was CMO at DMD biotech Prosensa at the time of its acquisition by BioMarin Pharmaceutical. Statement

> GenSight Biologics posted 72-week data from a Leber hereditary optic neuropathy gene therapy phase 3 trial. Release 

> Mereo BioPharma revealed it has wrapped up an end-of-phase 2 meeting with the FDA. The company thinks the regulatory progress will help with partnering discussions about chronic obstructive pulmonary disease prospect acumapimod. Statement 

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.